PharmacoEconomics

, Volume 22, Issue 7, pp 478–478 | Cite as

Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors’ Reply

  • Sean D. Sullivan
  • Kavita Patel
  • Jesse Green
Correspondence

Keywords

Major Public Health Concern Simulated Population Incremental Benefit Fibrosis Progression Male Cohort 

References

  1. 1.
    Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003 Jul; 290 (2): 228–37PubMedCrossRefGoogle Scholar
  2. 2.
    Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: riles, benefits, costs. JAMA 1998; 280: 2088–93PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Sean D. Sullivan
    • 1
  • Kavita Patel
    • 2
  • Jesse Green
    • 2
  1. 1.University of WashingtonSeattleUSA
  2. 2.RocheNutleyUSA

Personalised recommendations